Natural killer cells from children with type 1 diabetes have defects in NKG2D-dependent function and signaling

Diabetes

Volumn 60, Issue 3, 2011, Pages 857-866

  Qin, Huilian ^a   Lee, I Fang ^a   Panagiotopoulos, Constadina ^b   Wang, Xiaoxia ^a   Chu, Alvina D ^c   Utz, Paul J ^c   Priatel, John J ^a   Tan, Rusung ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 15; INTERLEUKIN 2; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; NATURAL KILLER CELL RECEPTOR NKG2D; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B;

ARTICLE; CELL FUNCTION; CHILD; CONTROLLED STUDY; CYTOKINE RELEASE; FEMALE; HUMAN; HUMAN CELL; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ADOLESCENT; ANALYSIS OF VARIANCE; CELLS, CULTURED; CHILD; DIABETES MELLITUS, TYPE 1; FLOW CYTOMETRY; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; INTERLEUKIN-15; INTERLEUKIN-2; KILLER CELLS, NATURAL; LYMPHOCYTE COUNT; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY K; SIGNAL TRANSDUCTION;

EID: 79952369448     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db09-1706     Document Type: Article

References (54)

1. Tisch R, McDevitt H. Insulin-dependent diabetes mellitus. Cell 1996;85:291-297 (Pubitemid 26160699)
2. Todd JA, Wicker LS. Genetic protection from the inflammatory disease type 1 diabetes in humans and animal models. Immunity 2001;15:387-395 (Pubitemid 32907386)
3. Flodström M, Maday A, Balakrishna D, Cleary MM, Yoshimura A, Sarvetnick N. Target cell defense prevents the development of diabetes after viral infection. Nat Immunol 2002;3:373-382 (Pubitemid 34308626)
4. Flodström M, Shi FD, Sarvetnick N, Ljunggren HG. The natural killer cell: friend or foe in autoimmune disease? Scand J Immunol 2002;55:432-441
5. Johansson S, Berg L, Hall H, Höglund P. NK cells: elusive players in autoimmunity. Trends Immunol 2005;26:613-618
6. Baxter AG, Smyth MJ. The role of NK cells in autoimmune disease. Autoimmunity 2002;35:1-14 (Pubitemid 34678715)
7. Poirot L, Benoist C, Mathis D. Natural killer cells distinguish innocuous and destructive forms of pancreatic islet autoimmunity. Proc Natl Acad Sci USA 2004;101:8102-8107 (Pubitemid 38698061)
8. Rodacki M, Milech A, de Oliveira JE. NK cells and type 1 diabetes. Clin Dev Immunol 2006;13:101-107 (Pubitemid 44950029)
9. Kataoka S, Satoh J, Fujiya H, et al. Immunologic aspects of the nonobese diabetic (NOD) mouse: abnormalities of cellular immunity. Diabetes 1983;32:247-253 (Pubitemid 13138268)
10. Carnaud C, Gombert J, Donnars O, Garchon H, Herbelin A. Protection against diabetes and improved NK/NKT cell performance in NOD.NK1.1 mice congenic at the NK complex. J Immunol 2001;166:2404-2411 (Pubitemid 32173475)
11. Poulton LD, Smyth MJ, Hawke CG, et al. Cytometric and functional analyses of NK and NKT cell deficiencies in NOD mice. Int Immunol 2001;13:887-896 (Pubitemid 32685201)
12. Johansson SE, Hall H, Björklund J, Höglund P. Broadly impaired NK cell function in non-obese diabetic mice is partially restored by NK cell activation in vivo and by IL-12/IL-18 in vitro. Int Immunol 2004;16:1-11 (Pubitemid 38054621)
13. Shultz LD, Schweitzer PA, Christianson SW, et al. Multiple defects in innate and adaptive immunologic function in NOD/LtSz-scid mice. J Immunol 1995;154:180-191
14. Herold KC, Huen A, Gould L, Traisman H, Rubenstein AH. Alterations in lymphocyte subpopulations in type 1 (insulin-dependent) diabetes mellitus: exploration of possible mechanisms and relationships to autoimmune phenomena. Diabetologia 1984;27(Suppl.):102-105 (Pubitemid 14096723)
15. Nair MP, Lewis EW, Schwartz SA. Immunoregulatory dysfunctions in type I diabetes: natural and antibody-dependent cellular cytotoxic activities. J Clin Immunol 1986;6:363-372 (Pubitemid 17195809)
16. Negishi K, Waldeck N, Chandy G, et al. Natural killer cell and islet killer cell activities in type 1 (insulin-dependent) diabetes. Diabetologia 1986;29:352-357 (Pubitemid 16060892)
17. Wilson RG, Anderson J, Shenton BK, White MD, Taylor RM, Proud G. Natural killer cells in insulin dependent diabetes mellitus. Br Med J (Clin Res Ed) 1986;293:244 (Pubitemid 16064229)
18. Hussain MJ, Alviggi L, Millward BA, Leslie RD, Pyke DA, Vergani D. Evidence that the reduced number of natural killer cells in type 1 (insulin-dependent) diabetes may be genetically determined. Diabetologia 1987;30:907-911 (Pubitemid 18055846)
19. Scheinin T, Mäenpää J, Kontiainen S. Immune responses to insulin and lymphocyte subclasses at diagnosis of insulin-dependent diabetes and one year later. Immunobiology 1990;180:431-440 (Pubitemid 20232375)
20. Lorini R, Moretta A, Valtorta A, et al. Cytotoxic activity in children with insulin-dependent diabetes mellitus. Diabetes Res Clin Pract 1994;23:37-42 (Pubitemid 24118513)
21. Biron CA, Nguyen KB, Pien GC, Cousens LP, Salazar-Mather TP. Natural killer cells in antiviral defense: function and regulation by innate cytokines. Annu Rev Immunol 1999;17:189-220 (Pubitemid 29241123)
22. Lanier LL. NK cell recognition. Annu Rev Immunol 2005;23:225-274 (Pubitemid 40563170)
23. Eagle RA, Trowsdale J. Promiscuity and the single receptor: NKG2D. Nat Rev Immunol 2007;7:737-744 (Pubitemid 47327391)
24. Raulet DH. Roles of the NKG2D immunoreceptor and its ligands. Nat Rev Immunol 2003;3:781-790 (Pubitemid 37328656)
25. Chang C, Dietrich J, Harpur AG, et al. Cutting edge: KAP10, a novel transmembrane adapter protein genetically linked to DAP12 but with unique signaling properties. J Immunol 1999;163:4651-4654 (Pubitemid 29501224)
26. Wu J, Song Y, Bakker AB, et al. An activating immunoreceptor complex formed by NKG2D and DAP10. Science 1999;285:730-732
27. Ogasawara K, Hamerman JA, Hsin H, et al. Impairment of NK cell function by NKG2D modulation in NOD mice. Immunity 2003;18:41-51 (Pubitemid 36120686)
28. Lee IF, Qin H, Priatel JJ, Tan R. Critical role for IFN-gamma in natural killer cell-mediated protection from diabetes. Eur J Immunol 2008;38:82-89
29. Lee IF, Qin H, Trudeau J, Dutz J, Tan R. Regulation of autoimmune diabetes by complete Freund's adjuvant is mediated by NK cells. J Immunol 2004;172:937-942 (Pubitemid 38113752)
30. Chan SM, Ermann J, Su L, Fathman CG, Utz PJ. Protein microarrays for multiplex analysis of signal transduction pathways. Nat Med 2004;10:1390-1396 (Pubitemid 40022723)
31. Saeed AI, Sharov V, White J, et al. TM4: a free, open-source system for microarray data management and analysis. Biotechniques 2003;34:374-378 (Pubitemid 36184095)
32. Fehniger TA, Caligiuri MA. Interleukin 15: biology and relevance to human disease. Blood 2001;97:14-32 (Pubitemid 32061238)
33. Malek TR. The biology of interleukin-2. Annu Rev Immunol 2008;26:453-479 (Pubitemid 351600382)
34. Priatel JJ, Utting O, Teh HS. TCR/self-antigen interactions drive double-negative T cell peripheral expansion and differentiation into suppressor cells. J Immunol 2001;167:6188-6194 (Pubitemid 33081546)
35. Stonier SW, Schluns KS. Trans-presentation: a novel mechanism regulating IL-15 delivery and responses. Immunol Lett 2010;127:85-92
36. Muntasell A, Magri G, Pende D, Angulo A, López-Botet M. Inhibition of NKG2D expression in NK cells by cytokines secreted in response to human cytomegalovirus infection. Blood 2010;115:5170-5179
37. Pende D, Cantoni C, Rivera P, et al. Role of NKG2D in tumor cell lysis mediated by human NK cells: cooperation with natural cytotoxicity receptors and capability of recognizing tumors of nonepithelial origin. Eur J Immunol 2001;31:1076-1086
38. Pende D, Rivera P, Marcenaro S, et al. Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes: analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity. Cancer Res 2002;62:6178-6186 (Pubitemid 35244469)
39. Upshaw JL, Leibson PJ. NKG2D-mediated activation of cytotoxic lymphocytes: unique signaling pathways and distinct functional outcomes. Semin Immunol 2006;18:167-175 (Pubitemid 43817560)
40. Upshaw JL, Arneson LN, Schoon RA, Dick CJ, Billadeau DD, Leibson PJ. NKG2D-mediated signaling requires a DAP10-bound Grb2-Vav1 intermediate and phosphatidylinositol-3-kinase in human natural killer cells. Nat Immunol 2006;7:524-532
41. Rodacki M, Svoren B, Butty V, et al. Altered natural killer cells in type 1 diabetic patients. Diabetes 2007;56:177-185
42. Horng T, Bezbradica JS, Medzhitov R. NKG2D signaling is coupled to the interleukin 15 receptor signaling pathway. Nat Immunol 2007;8:1345-1352 (Pubitemid 350138973)
43. Zafirova B, Mandarić S, Antulov R, et al. Altered NK cell development and enhanced NK cell-mediated resistance to mouse cytomegalovirus in NKG2D-deficient mice. Immunity 2009;31:270-282
44. Kim S, Poursine-Laurent J, Truscott SM, et al. Licensing of natural killer cells by host major histocompatibility complex class I molecules. Nature 2005;436:709-713 (Pubitemid 41117274)
45. Sun JC, Beilke JN, Lanier LL. Adaptive immune features of natural killer cells. Nature 2009;457:557-561
46. Sun JC, Lanier LL. Tolerance of NK cells encountering their viral ligand during development. J Exp Med 2008;205:1819-1828
47. Tripathy SK, Keyel PA, Yang L, et al. Continuous engagement of a self-specific activation receptor induces NK cell tolerance. J Exp Med 2008;205:1829-1841
48. Oppenheim DE, Roberts SJ, Clarke SL, et al. Sustained localized expression of ligand for the activating NKG2D receptor impairs natural cytotoxicity in vivo and reduces tumor immunosurveillance. Nat Immunol 2005;6:928-937 (Pubitemid 43090448)
49. Zitvogel L. Dendritic and natural killer cells cooperate in the control/switch of innate immunity. J Exp Med 2002;195:F9-F14 (Pubitemid 34461485)
50. Takahashi K, Aranami T, Endoh M, Miyake S, Yamamura T. The regulatory role of natural killer cells in multiple sclerosis. Brain 2004;127:1917-1927 (Pubitemid 39150251)
51. Zhang B, Yamamura T, Kondo T, Fujiwara M, Tabira T. Regulation of experimental autoimmune encephalomyelitis by natural killer (NK) cells. J Exp Med 1997;186:1677-1687 (Pubitemid 27506281)
52. Erkeller-Yüsel F, Hulstaart F, Hannet I, Isenberg D, Lydyard P. Lymphocyte subsets in a large cohort of patients with systemic lupus erythematosus. Lupus 1993;2:227-231 (Pubitemid 23295636)
53. Takeda K, Dennert G. The development of autoimmunity in C57BL/6 lpr mice correlates with the disappearance of natural killer type 1-positive cells: evidence for their suppressive action on bone marrow stem cell proliferation, B cell immunoglobulin secretion, and autoimmune symptoms. J Exp Med 1993;177:155-164 (Pubitemid 23008095)
54. Yabuhara A, Yang FC, Nakazawa T, et al. A killing defect of natural killer cells as an underlying immunologic abnormality in childhood systemic lupus erythematosus. J Rheumatol 1996;23:171-177 (Pubitemid 26037216)